Galectin Q2 net loss $9.2M; NAVIGATE trial interim analysis expected Q4 2024

GALECTIN THERAPEUTICS INC

2023-Q2 EPS reported -$0.35

Net loss per share $0.15 for Q2 2023 vs $0.16 in Q2 2022; R&D expenses $7.4M down from $8.1M.
Cash and equivalents $18.0M as of June 30, 2023; additional $30M available under chairman's credit line.
NAVIGATE trial (NASH cirrhosis) fully randomized with 357 patients; Phase 2b interim analysis expected Q4 2024.
Company evaluating Phase 2 trial of belapectin plus Keytruda in advanced head and neck cancers.
Belapectin safety profile remains encouraging; no approved therapy for NASH cirrhosis with portal hypertension.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GALECTIN THERAPEUTICS INC reported the three months ended June 30, 2023 results: net income a net loss applicable to common stockholders of $9.2 million, or ($0.15) per share, EPS ($0.15) per share.

Period: the three months ended June 30, 2023
Net income: a net loss applicable to common stockholders of $9.2 million, or ($0.15) per share
EPS: ($0.15) per share
Result: reported results

Exact text from the filing

For the three months ended June 30, 2023, the Company reported a net loss applicable to common stockholders of $9.2 million, or ($0.15) per share

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GALECTIN THERAPEUTICS INC reported financial results for the six months ended June 30, 2023.

Period: the six months ended June 30, 2023
Result: reported results

Exact text from the filing

announcing its results of operations and financial condition as of and for the three and six months ended June 30, 2023

View on SEC.gov

Browse all earnings releases →

GALECTIN THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001140361-23-039412

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.